Oraya Therapeutics Publishes Results of Wet AMD Treatment Study

Oraya Therapeutics, Newark, Calif.-based minimally invasive ophthalmic treatment company, has published the results of a study analyzing the effectiveness and safety of its wet age-related macular degeneration therapy in Ophthalmology.

Advertisement
Carrie Pallardy

The INTREPID study demonstrated that Oraya Therapy Stereotactic Radiotherapy decreased the amount of anti-VEGF injections needed to treat macular degeneration patients.

More Articles on Ophthalmology:
3 Statistics on Cataract Surgery Procedure Times in ASCs
Abbott Medical Optics Appoints Dr. David Tanzer Chief Medical Officer
Hubble Telemedical Launches EyeQ Wellness Exam

AI’s next act in healthcare: Why business model innovation matters more than tech stacks

Recommended Whitepaper

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt

  • American Board of Ophthalmology names CEO

    The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

    By: Cameron Cortigiano
Advertisement

Comments are closed.